Fox Chase Cancer Center researchers confirmed that the mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals.
UC Davis Health has successfully treated its first patient with chimeric antigen receptor T cells created in its cellular therapy lab. UC Davis is now one of only a few medical centers in California manufacturing CAR T cells on-site.
An online symptom management tool using expressive writing could help women with ovarian cancer better manage complex symptoms, according to a new study led by a University of Pittsburgh and UPMC nurse-scientist.
Researchers at the University of Kansas Medical Center, Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center, Brown University School of Public Health, and the University of California San Francisco have introduced a novel immune-profiling method capable of reporting specific immune cell types using only DNA from blood, rather than from fresh cell samples.
Immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released by the President’s Cancer Panel.
A study led by investigators at the University of Alabama at Birmingham and Nationwide Children’s Hospital has provided additional evidence of the efficacy of virotherapy for glioblastoma.
Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a novel combination of Pfizer’s Ibrance (palbociclib) and Millennium Pharmaceuticals’ sapanisertib, delivered in a nanoparticle formulation, extended the survival of mice with medulloblastoma.
A new risk score can identify men and women under age 50 most likely to develop colorectal cancer, according to an international study led by researchers at NYU Langone Health and the Laura and Isaac Perlmutter Cancer Center.
Results from the pivotal phase III KEYNOTE-775/Study 309 trial, evaluating the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting, showed the combination led to significantly longer progression-free survival and overall survival.
